Gouty Arthritis Market is Gaining Significant Traction with ROMEG Therapeutics Receiving the U.S. FDA Approval for its GLOPERBA (colchicine) Oral Solution, 0.6 mg/5 mL for Prophylaxis of Gout Flares in Adults

 

Gouty arthritis is a type of arthritis that causes inflammation, typically in one joint, which begins suddenly. Gouty arthritis is caused by the deposition of needle-shaped crystals of uric acid in a joint. The primary symptoms of gouty arthritis include severe pain, swelling, and redness in joints, often in the big toe. 

Increasing prevalence of gout with rising alcohol consumption is expected to drive growth of the global gouty arthritis market. According to the Centers for Disease Control and Prevention (CDC), from 2013-2015 around 54.4 million adults in the U.S. have some form of arthritis, gout, rheumatoid arthritis, or fibromyalgia. According to the Arthritis Foundation, 8 million people in the U.S. suffer from gout arthritis every year. According to the same source, high intake of sugary or alcoholic drinks is one of the major risk factors for gout arthritis. Alcohol is a major source of purine, which produces uric acid. High levels of uric acids in the body can result in the formation of crystals of uric acid, eventually leading to gout. Hence, such factors are expected to drugs market is expected to drive growth of the global gouty arthritis market. Furthermore, increasing adoption of biologics and increasing R&D activities in regenerative medicines is expected to propel the global gouty arthritis market growth in the near future.

Side-effects associated with therapeutics drugs and high indirect costs of gout therapeutics are expected to hamper the global gouty arthritis market growth in the near future. Besides, lack of awareness among the medical fraternity regarding effective treatment of the condition, typically in emerging economies is expected to restrain growth of the market. Among regions, North America is expected to witness significant growth in the global gouty arthritis market. This is owing to high prevalence of gouty arthritis in the U.S. According to the clinical guidelines for gout published in Annals of Internal Medicine, in 2017, around 3.9% of U.S. adults aged 20 years and above reported gout at least once in a lifetime. Furthermore, Asia Pacific is expected to register a robust growth rate, owing to rising number of patients suffering from chronic diseases such as cardiovascular disease across the region.

Key companies involved in the global gouty arthritis market are Lannett Company, Inc., Teijin Pharma Ltd, Boehringer Ingelheim, Takeda Pharmaceutical Company Ltd, GlaxoSmithKline plc, ROMEG Therapeutics, LLC, Horizon Therapeutics plc, Regeneron Pharmaceuticals, Mylan NV, Merck& Co. Inc., and Novartis International AG.

For instance, in February 2019, ROMEG Therapeutics, LLC received the U.S. Food and Drug Administration (FDA) approval for its GLOPERBA (colchicine) Oral Solution, 0.6 mg/5 mL for prophylaxis of gout flares in adults.